Mereo BioPharma Group/$MREO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Primary listing
Employees
36
Headquarters
Website
MREO Metrics
BasicAdvanced
$302M
-
-$0.32
0.42
-
Price and volume
Market cap
$302M
Beta
0.42
52-week high
$4.23
52-week low
$1.47
Average daily volume
1.5M
Financial strength
Current ratio
8.128
Quick ratio
7.923
Total debt to equity
1.109
Interest coverage (TTM)
-47.82%
Profitability
EBITDA (TTM)
-44.01
Gross margin (TTM)
73.60%
Net profit margin (TTM)
-9,909.60%
Operating margin (TTM)
-8,923.40%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-35.13%
Return on equity (TTM)
-74.61%
Valuation
Price to revenue (TTM)
595.425
Price to book
5.58
Price to tangible book (TTM)
5.62
Price to free cash flow (TTM)
-8.956
Free cash flow yield (TTM)
-11.17%
Free cash flow per share (TTM)
-0.212
Growth
Revenue change (TTM)
-50.00%
Earnings per share change (TTM)
20.07%
3-year earnings per share growth (CAGR)
-13.65%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
Bulls say / Bears say
Strong cash position: $62.5 million as of March 31, 2025, anticipated to fund operations into 2027, lessening near-term financing risk and backing late-stage development (Reuters).
Multiple regulatory designations: setrusumab has orphan drug status from both the EC and FDA, PRIME designation from the EMA, and Breakthrough Therapy designation from the FDA; alvelestat received a positive EMA opinion on orphan designation (final decision expected Q1 2025), strengthening approval prospects (Reuters).
Phase 3 program remains on track: global Orbit and Cosmic studies for setrusumab are progressing toward a second interim analysis in mid-2025 and final data in Q4 2025, with consistent safety profiles supporting continued clinical momentum (Reuters).
Shares plunged 33.7% on July 10, 2025 after the Orbit Phase 3 trial failed to meet early stopping criteria, highlighting high clinical risk and increased investor volatility (Barron's).
The second interim analysis of the setrusumab trial did not reach the statistical threshold for early termination, pointing to efficacy challenges and a longer runway to possible approval (Barron's).
Ultragenyx’s gene therapy (UX111) received a complete response letter from the FDA due to manufacturing concerns, reflecting possible regulatory execution issues for Mereo’s key partner and a risk that resources could be diverted (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mereo BioPharma Group stock?
Mereo BioPharma Group (MREO) has a market cap of $302M as of November 04, 2025.
What is the P/E ratio for Mereo BioPharma Group stock?
The price to earnings (P/E) ratio for Mereo BioPharma Group (MREO) stock is 0 as of November 04, 2025.
Does Mereo BioPharma Group stock pay dividends?
No, Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Mereo BioPharma Group dividend payment date?
Mereo BioPharma Group (MREO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mereo BioPharma Group?
Mereo BioPharma Group (MREO) has a beta rating of 0.42. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.